高级检索
当前位置: 首页 > 详情页

Dual inhibitors of Histone Deacetylases and Other Cancer-Related Targets: A Pharmacological Perspective.

文献详情

资源类型:
Pubmed体系:
机构: [a]Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, [b]Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, [c]Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, [d]College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People’s Republic of China. [e]School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510000, People’s Republic of China. [f]Department of Basic Medicine, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People’s Republic of China. [g]INSERM, U1231, Label LipSTIC, and Ligue Nationale contre le Cancer, Dijon, France. [h]Université de Bourgogne-Franche Comté, I-SITE, France. [i]University Hospital of Dijon (CHU). jAnti-cancer Center George-François Leclerc, CGFL, Dijon, France
出处:
ISSN:

摘要:
Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clinical trials. Recently, dual targeting strategy comprising the HDACs component has emerged as an alternative approach for combination therapies. In this perspective, we intend to gather all HDACs-containing dual inhibitors related to cancer therapy published in literature since 2015, classify them into five categories based on targets' biological functions, and discuss the rationale why dual acting agents should work better than combinatorial therapies using two separate drugs. The article discusses the pharmacological aspects of these dual inhibitors, including in vitro biological activities, pharmacokinetic studies, in vivo efficacy studies, as well as available clinical trials. The review of the current status and advances should provide better analysis for future opportunities and challenges of this field. Copyright © 2020 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学
第一作者:
第一作者机构: [a]Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, [b]Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, [c]Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, [d]College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People’s Republic of China. [e]School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510000, People’s Republic of China.
通讯作者:
通讯机构: [a]Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, [b]Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, [c]Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, [d]College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People’s Republic of China. [g]INSERM, U1231, Label LipSTIC, and Ligue Nationale contre le Cancer, Dijon, France. [h]Université de Bourgogne-Franche Comté, I-SITE, France.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2023 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号